| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22b9baa71ceef111b94d9fcf4391f1f0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f52c68e4149a6c462b850d4e7cc2b2f9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-103
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1072
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-1096
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K103-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-10 |
| filingDate |
2018-09-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aeb9c4a3428449d13494f93c6b59ada3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74d2aa7a4c7e61fc033091b5138a9f4c |
| publicationDate |
2018-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CO-2018010024-A2 |
| titleOfInvention |
Radiopharmaceutical complexes |
| abstract |
The invention provides a method for the formation of a thorium complex directed to tissue, comprising; a) forming an octadentated chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N position with a methyl group and a coupling moiety ending in a carboxylic acid group; b) coupling said octadentated chelator with at least one tissue directed residue pointing to HER2; and c) contacting said tissue directed chelator with an aqueous solution comprising an ion of at least one alpha-emitting thorium isotope. A method of treating a neoplastic or hyperplastic disease is also provided which comprises the administration of such a thorium complex directed to tissue, as well as the complex and the corresponding pharmaceutical formulations. |
| priorityDate |
2016-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |